Get the Stockscreener App
0.0111
0.00%
0.00
Virpax Pharmaceuticals Inc stock is traded at $0.0111, with a volume of 1,033.
It is up +0.00% in the last 24 hours and up +11,000% over the past month.
See More
Previous Close:
$0.0111
Open:
$0.0111
24h Volume:
1,033
Relative Volume:
2.69
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-12.07M
P/E Ratio:
-0.00105
EPS:
-10.6183
Net Cash Flow:
$-16.71M
1W Performance:
+11,000%
1M Performance:
+11,000%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.0111
$0.0111
1-Week Range:
$0.0111
$0.0111
52-Week Range:
$0.0001
$0.021
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.0111 | 0 | 0 | -12.07M | -16.71M | -10.62 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals, Inc. Revenue Breakdown – OTC:VRPX - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to EBITDA forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to book forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to sales forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to revenue forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax Pharmaceuticals, Inc. Actuals & Estimates (OTC:VRPX) - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Nigeria
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
ENSCW Stock Price, News & Analysis - Stock Titan
BTAX Stock Price, News & Analysis - Stock Titan
QBIO Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
XSNX Stock Price, News & Analysis - Stock Titan
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax reports positive results in Probudur dog study - Investing.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - Stock Titan
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
User - The Chronicle-Journal
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Virpax Pharmaceuticals Inc. (VRPX) Quarterly 10-Q Report - qz.com
ADM’s multiple accounting errors and SEC probe are ‘highly concerning’ to investors - Fortune
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - citybiz
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - The Chronicle-Journal
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - The Chronicle-Journal
Virpax Regains Compliance with Nasdaq Minimum Bid Price - Business Wire
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
Cap:
|
Volume (24h):